Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kiyotaka Yamazaki"'
Publikováno v:
Infectious Diseases and Therapy, Vol 8, Iss 2, Pp 285-299 (2019)
Abstract Introduction Japan has one of the highest prevalence rate of chronic hepatitis C (CHC) in the industrialized world. However, the burden of CHC treatment is poorly understood. Thus, the healthcare resource utilization and costs of treated ver
Externí odkaz:
https://doaj.org/article/778ede28a15147a78acb15adb46dcd04
Publikováno v:
Cancer Science
Treatment‐free remission (TFR), in which patients discontinue pharmacotherapy and remain in molecular remission, is an emerging treatment goal for patients with chronic myeloid leukemia (CML). Attainment of TFR requires an increased frequency of mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db51312689295e7a8319f6150078932e
https://pubmed.ncbi.nlm.nih.gov/32324296
https://pubmed.ncbi.nlm.nih.gov/32324296
Autor:
Toshiro Tango, Shuichi Komatsu, Tsutomu Takeuchi, Yoshiya Tanaka, Kiyotaka Yamazaki, Ataru Igarashi, Ryo Nakajima
Publikováno v:
Modern Rheumatology. 28:39-47
The objective of this study is to evaluate the economic impact of adalimumab (ADA) on Japanese rheumatoid arthritis (RA) patients.ANOUVEAU was a 48-week multicenter, prospective, observational, single-cohort study. Work-related outcomes including abs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b688a1447a736e64b75ff8df24ed8d
https://doi.org/10.1080/14397595.2017.1341459
https://doi.org/10.1080/14397595.2017.1341459
Autor:
Yoshiya Tanaka, Naoki Agata, Tomohiro Nakamura, Ryo Nakajima, Toshiro Tango, Ataru Igarashi, Shuichi Komatsu, Tsutomu Takeuchi, Kiyotaka Yamazaki
Publikováno v:
Advances in Therapy
Introduction The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a148419f3ee6e7be9d208d08a897ce03
http://europepmc.org/articles/PMC5350205
http://europepmc.org/articles/PMC5350205
Autor:
Kiyotaka Yamazaki, Suchin Virabhak, Kikuo Yasui, Scott J. Johnson, Dominic Mitchell, Jennifer C. Samp, Ataru Igarashi, Cammy Yuen
Publikováno v:
Journal of medical economics. 19(12)
This study compared the cost-effectiveness of chronic hepatitis C virus (HCV) genotype 1b (GT1b) therapy ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) vs daclatasvir + asunaprevir (DCV/ASV) and no treatment in patients without cirrhosis. Cost-effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf04af2159d59a90eb9d72d26a06c80e
https://pubmed.ncbi.nlm.nih.gov/27348464
https://pubmed.ncbi.nlm.nih.gov/27348464
Publikováno v:
Advances in Therapy
Introduction Crohn’s disease (CD) is a chronic and progressive disease in which the long-term management is important. This study sought to assess treatment persistence and dose escalation in the maintenance phase with adalimumab (ADA) or inflixima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07e5b1e815edb825389b808552e6efc
https://pubmed.ncbi.nlm.nih.gov/27664107
https://pubmed.ncbi.nlm.nih.gov/27664107
Autor:
Yoshiya Tanaka, Kiyotaka Yamazaki, Ryo Nakajima, Shuichi Komatsu, Ataru Igarashi, Toshiro Tango, Tsutomu Takeuchi
Publikováno v:
Modern Rheumatology; 2018, Vol. 28 Issue 1, p39-47, 9p